Treatment of recurrent nodular goiters with percutaneous ethanol injection: A clinical study of twelve patients

Tamas Solymosi, I. Gál

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Twelve patients who had previously undergone thyroid surgery received percutaneous ethanol injection (PEI) treatment because of recurrent nodular goiter (3 with a toxic [TN], 2 with a nontoxic cystic [NCN], and 7 with a nontoxic solid nodule [NSN]). Two of the 12 had recurrent nerve palsy contralateral to the nodule. Each patient received a mean total dose of 0.88 mL of ethanol per milliliter of nodular volume. Ethanol was injected in a mean of 3.5 sessions for solid and 3 sessions for NCN. In most cases, a slight to moderate burning pain was experienced during and for 12-48 hours after PEI treatment, and one patient experienced temporary hoarseness. One patient with TN and 2 patients with NSN became hypothyroid, 7 patients with nontoxic nodules remained euthyroid, 1 with TN became euthyroid, and a previously hyperthyroid patient with TN became subclinically hyperthyroid 1-year posttherapy. The nodule shrank by more than 50% of the pretreatment volume in all patients (8.6 ± 2.6 vs. 2.9 ± 1.2 mL in TN, and 12.3 ± 4.9 vs. 4.16 ± 2.54 mL in nontoxic nodules, pretreatment vs. 1 year posttreatment volume, respectively). With regard to the increased risk of reoperation, PEI treatment can be proposed for patients with recurrent nodular goiter requiring surgery.

Original languageEnglish
Pages (from-to)273-277
Number of pages5
JournalThyroid
Volume13
Issue number3
Publication statusPublished - Mar 1 2003

Fingerprint

Nodular Goiter
Ethanol
Injections
Therapeutics
Hyperthyroidism
Clinical Studies
Hoarseness
Poisons
Reoperation
Paralysis
Thyroid Gland
Pain

ASJC Scopus subject areas

  • Endocrinology

Cite this

Treatment of recurrent nodular goiters with percutaneous ethanol injection : A clinical study of twelve patients. / Solymosi, Tamas; Gál, I.

In: Thyroid, Vol. 13, No. 3, 01.03.2003, p. 273-277.

Research output: Contribution to journalArticle

@article{b2842adaf6e443ee94973c23f2a9f8d8,
title = "Treatment of recurrent nodular goiters with percutaneous ethanol injection: A clinical study of twelve patients",
abstract = "Twelve patients who had previously undergone thyroid surgery received percutaneous ethanol injection (PEI) treatment because of recurrent nodular goiter (3 with a toxic [TN], 2 with a nontoxic cystic [NCN], and 7 with a nontoxic solid nodule [NSN]). Two of the 12 had recurrent nerve palsy contralateral to the nodule. Each patient received a mean total dose of 0.88 mL of ethanol per milliliter of nodular volume. Ethanol was injected in a mean of 3.5 sessions for solid and 3 sessions for NCN. In most cases, a slight to moderate burning pain was experienced during and for 12-48 hours after PEI treatment, and one patient experienced temporary hoarseness. One patient with TN and 2 patients with NSN became hypothyroid, 7 patients with nontoxic nodules remained euthyroid, 1 with TN became euthyroid, and a previously hyperthyroid patient with TN became subclinically hyperthyroid 1-year posttherapy. The nodule shrank by more than 50{\%} of the pretreatment volume in all patients (8.6 ± 2.6 vs. 2.9 ± 1.2 mL in TN, and 12.3 ± 4.9 vs. 4.16 ± 2.54 mL in nontoxic nodules, pretreatment vs. 1 year posttreatment volume, respectively). With regard to the increased risk of reoperation, PEI treatment can be proposed for patients with recurrent nodular goiter requiring surgery.",
author = "Tamas Solymosi and I. G{\'a}l",
year = "2003",
month = "3",
day = "1",
language = "English",
volume = "13",
pages = "273--277",
journal = "Thyroid",
issn = "1050-7256",
publisher = "Mary Ann Liebert Inc.",
number = "3",

}

TY - JOUR

T1 - Treatment of recurrent nodular goiters with percutaneous ethanol injection

T2 - A clinical study of twelve patients

AU - Solymosi, Tamas

AU - Gál, I.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Twelve patients who had previously undergone thyroid surgery received percutaneous ethanol injection (PEI) treatment because of recurrent nodular goiter (3 with a toxic [TN], 2 with a nontoxic cystic [NCN], and 7 with a nontoxic solid nodule [NSN]). Two of the 12 had recurrent nerve palsy contralateral to the nodule. Each patient received a mean total dose of 0.88 mL of ethanol per milliliter of nodular volume. Ethanol was injected in a mean of 3.5 sessions for solid and 3 sessions for NCN. In most cases, a slight to moderate burning pain was experienced during and for 12-48 hours after PEI treatment, and one patient experienced temporary hoarseness. One patient with TN and 2 patients with NSN became hypothyroid, 7 patients with nontoxic nodules remained euthyroid, 1 with TN became euthyroid, and a previously hyperthyroid patient with TN became subclinically hyperthyroid 1-year posttherapy. The nodule shrank by more than 50% of the pretreatment volume in all patients (8.6 ± 2.6 vs. 2.9 ± 1.2 mL in TN, and 12.3 ± 4.9 vs. 4.16 ± 2.54 mL in nontoxic nodules, pretreatment vs. 1 year posttreatment volume, respectively). With regard to the increased risk of reoperation, PEI treatment can be proposed for patients with recurrent nodular goiter requiring surgery.

AB - Twelve patients who had previously undergone thyroid surgery received percutaneous ethanol injection (PEI) treatment because of recurrent nodular goiter (3 with a toxic [TN], 2 with a nontoxic cystic [NCN], and 7 with a nontoxic solid nodule [NSN]). Two of the 12 had recurrent nerve palsy contralateral to the nodule. Each patient received a mean total dose of 0.88 mL of ethanol per milliliter of nodular volume. Ethanol was injected in a mean of 3.5 sessions for solid and 3 sessions for NCN. In most cases, a slight to moderate burning pain was experienced during and for 12-48 hours after PEI treatment, and one patient experienced temporary hoarseness. One patient with TN and 2 patients with NSN became hypothyroid, 7 patients with nontoxic nodules remained euthyroid, 1 with TN became euthyroid, and a previously hyperthyroid patient with TN became subclinically hyperthyroid 1-year posttherapy. The nodule shrank by more than 50% of the pretreatment volume in all patients (8.6 ± 2.6 vs. 2.9 ± 1.2 mL in TN, and 12.3 ± 4.9 vs. 4.16 ± 2.54 mL in nontoxic nodules, pretreatment vs. 1 year posttreatment volume, respectively). With regard to the increased risk of reoperation, PEI treatment can be proposed for patients with recurrent nodular goiter requiring surgery.

UR - http://www.scopus.com/inward/record.url?scp=0037364289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037364289&partnerID=8YFLogxK

M3 - Article

C2 - 12729476

AN - SCOPUS:0037364289

VL - 13

SP - 273

EP - 277

JO - Thyroid

JF - Thyroid

SN - 1050-7256

IS - 3

ER -